Jasper Therapeutics (JSPR) news

Jasper Therapeutics reports second quarter 2026 financial results and provides corporate update

Jasper Therapeutics, Inc. (Nasdaq: JSPR) reported its first quarter 2026 financial results and provided a corporate update on May 14, 2026. As of March 31, 2026, the company held $14.1 million in cash and cash equivalents, a decrease from $28.7 million as of December 31, 2025. For the three months…

Jasper Therapeutics Q2 EPS USD -0.1 vs. IBES estimate USD -0.35

Jasper Therapeutics Q2 net income USD -2.8 million

Jasper Therapeutics, Inc. (Nasdaq: JSPR) reported a net loss of $15.0 million for the second quarter of 2024, or $0.97 per basic and diluted share, compared to net loss of $16.08 million in the same period in 2023. The company’s financial performance reflects ongoing investment in its clinical…

Jasper Therapeutics - announces $132 mln private placement of convertible preferred stock

Jasper Therapeutics has announced a private placement of convertible preferred stock, raising $132 million in funding. The transaction is intended to support the company’s ongoing research and development initiatives, as well as to strengthen its financial position for future growth. The…

Jasper Therapeutics - combined company operations expected to be funded through second half of 2028

Jasper Therapeutics, Inc. (NASDAQ: JSPR) has outlined that its combined company operations are expected to be funded through the second half of 2028, based on current financial projections and ongoing capital-raising activities. As of March 31, 2025, the company held $48.8 million in cash , and it…